HeXun Biosciences Co (ROCO:6986) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
37 GF Score
Price NT$43.00
GF Value NT$109.13
Valuation Significantly Undervalued
View Full Analysis

What is HeXun Biosciences Co Net Loan?

Net Loan only applies to banks and insurance companies.

ROCO:6986
37GF Score
HeXun Biosciences Co Ltd ROCO:6986
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HeXun Biosciences Co (ROCO:6986) Overvalued in 2026?

Based on GuruFocus' analysis, HeXun Biosciences Co stock appears to be undervalued. The current stock price of NT$43.00 is trading 60.6% below its estimated GF Value™ of NT$109.13. GuruFocus considers HeXun Biosciences Co to be Significantly Undervalued.

Key valuation signals for ROCO:6986:

  • Net Loan:
  • GF Value™: NT$109.13 vs. price of NT$43.00 (60.6% below fair value)
  • GF Score™: 37/100

No single metric tells the full story. See the ROCO:6986 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
37GF Score

Get the complete analysis for ROCO:6986

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$43.00
Price
NT$109.13
GF Value